A Study of Imlunestrant (LY3484356) in Healthy Women
Completed · Phase 1
Conditions studied: Healthy
In brief
The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of non-childbearing potential. This study will last up to approximately 6 weeks for each participant including the screening period.
Key facts
- Study ID
- NCT05509816
- Run by
- Eli Lilly and Company
- People needed
- 20
- Starts
- 2022-09-12
- Expected to finish
- 2022-11-30
- Last updated by the study team
- 2025-11-12
Who can join
Age: 18 and older, up to 65. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Women not of childbearing potential
- Participants who are overtly healthy as determined by medical assessment
- Participants with body mass index (BMI) of 18.0 and 35.0 kilograms per meter squared (kg/m²), inclusive
You may not qualify if…
- Have known allergies to imlunestrant, related compounds or any components of the formulation or midazolam
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
- Use or intend to use medications that are substrate drugs of P-glycoprotein
Where it is running
- LabCorp CRU, Inc. — Daytona Beach, Florida, United States
- LabCorp CRU, Inc. — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.